Skip to main content
Clinical Trials/NCT06447181
NCT06447181
Not Yet Recruiting
N/A

A Retrospective Cohort Study of Three- Dimensional Visualization Combined With ICG Molecular Fluorescence Imaging in Hepatolithiasis.

Zhujiang Hospital1 site in 1 country100 target enrollmentAugust 30, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatolithiasis
Sponsor
Zhujiang Hospital
Enrollment
100
Locations
1
Primary Endpoint
operation time
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

This study adopted a retrospective study method to explore the clinical application value of 3D visualization combined with ICG molecular fluorescence imaging technology in hepatolithiasis, and further analyze whether 3D visualization combined with ICG molecular fluorescence imaging technology can improve the prognosis of hepatolithiasis by comparing with conventional surgery.

Detailed Description

Hepatolithiasis is a complex and intractable benign disease, often called "benign disease with poor prognosis". Clinical practice has proved that the diagnosis and treatment platform for hepatolithiasis built by modern digital image technologies such as 3D visualization and Indocine green fluorescence image navigation technology plays a vital leading role in accurate preoperative assessment, location of the lesion, formulation of the best surgical plan, and intraoperative navigation to avoid collateral damage. The clinical practice has proved that the diagnosis and treatment platform for hepatolithiasis built by modern digital image technologies such as 3D visualization and ICG fluorescence image navigation plays a vital leading role in accurate preoperative assessment, location of the lesion, formulation of the best surgical plan, and intraoperative navigation to avoid collateral damage.Therefore, we want to conduct a retrospective cohort study to explore the application value of 3D visualization combined with ICG fluorescence technology in hepatolithiasis, in order to further improve the curative effect of hepatolithiasis.

Registry
clinicaltrials.gov
Start Date
August 30, 2024
End Date
December 30, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Zhujiang Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged ≥18 years, of any gender; The diagnosis was hepatolithiasis;Surgical treatment has been performed.

Exclusion Criteria

  • Patients with severe cardiac, pulmonary, cerebral, renal dysfunction or other clinical contraindications who are unable to tolerate surgical treatment; Patients with malignant transformation; Lack of clinical data.

Outcomes

Primary Outcomes

operation time

Time Frame: Perioperative period

minutes

intraoperative incidental injuries

Time Frame: Perioperative period

intraoperative blood loss

Time Frame: Perioperative period

ml

Secondary Outcomes

  • Postoperative complications(Perioperative period)
  • Repeat surgery rate(Perioperative period)
  • Serum bilirubin levels(Perioperative period)

Study Sites (1)

Loading locations...

Similar Trials